Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.39 |
| ▸ | TSHR | P16473 | 4/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | MIF | P14174 | 2/20 | 0.39 |
| ▸ | CD74 | P04233 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.38 |
| ▸ | FYN | P06241 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.37 |
| ▸ | BCR | P11274 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1147802 | 0.89 | ABL1 (0.41) | MAPTRAB9ALMNANPC1ABL1 | |
| SCHEMBL1148184 | 0.87 | GAA (0.41) | MAPTRAB9ALMNANPC1SMN1; SMN2 | |
| SCHEMBL1148468 | 0.84 | MEN1 (0.39) | TSHRRAB9ALMNAALDH1A1NPC1 | |
| SCHEMBL1147867 | 0.83 | DHODH (0.38) | HDAC4HDAC8DHODHABL1ABCB1 | |
| SCHEMBL1148350 | 0.82 | ALOX5 (0.41) | MAPTRAB9ADHODHALDH1A1NPC1 | |
| SCHEMBL1148485 | 0.82 | ESR2 (0.41) | MAPTRAB9ALMNADHODHFYN | |
| SCHEMBL1148326 | 0.82 | ALOX5 (0.37) | MAPTTSHRLMNAMIFALDH1A1 | |
| SCHEMBL1148596 | 0.81 | MTNR1A (0.34) | MAPTTSHRLMNADHODHHSD17B10 | |
| SCHEMBL931399 | 0.81 | GAA (0.42) | MAPTTSHRLMNAHDAC4HDAC8 | |
| SCHEMBL1148452 | 0.80 | ESR2 (0.42) | MIFCYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188075-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2012-05-29 | — | — | US | claimed |
| EP-2298748-A2 | Triazole compounds that modulate HSP90 activity | Synta Pharmaceuticals Corp. (US) | 2011-03-23 | — | — | EP | claimed |
| US-7825148-B2 | heat shock protein 90 inhibitors such as 3-(2-Hydroxyphenyl)-4-(naphthalen-1-yl)-5-mercapto-triazole, used for for preventing or treating hyperproliferative disorders, such as cancer | SYNTA PHARMACEUTICALS CORP. (US) | 2010-11-02 | — | — | US | claimed |
| US-20100093717-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP | 2010-04-15 | — | — | US | claimed |
| EP-2054059-A2 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | Synta Pharmaceuticals Corporation (US) | 2009-05-06 | — | — | EP | claimed |
| WO-2008021364-A2 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2008-02-21 | — | — | WO | claimed |
| EP-1817295-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | Synta Pharmaceuticals Corporation (US) | 2007-08-15 | — | — | EP | claimed |
| WO-2006055760-A9 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP (US) | 2006-09-21 | — | — | WO | claimed |
| US-20060167070-A1 | heat shock protein 90 inhibitors such as 3-(2-Hydroxyphenyl)-4-(naphthalen-1-yl)-5-mercapto-triazole, used for for preventing or treating hyperproliferative disorders, such as cancer | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2006-07-27 | — | — | US | claimed |
| WO-2006055760-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2006-05-26 | — | — | WO | claimed |
| US-20190144398-A1 | METHOD FOR TREATING INFLAMMATORY DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2019-05-16 | — | — | US | disclosed |
| US-20170320837-A1 | METHOD FOR TREATING INFLAMMATORY DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2017-11-09 | — | — | US | disclosed |
| EP-2295416-B1 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP (US) | 2016-01-27 | — | — | EP | disclosed |
| US-9108933-B2 | Method for treating proliferative disorders associated with mutations in c-Met | SYNTA PHARMACEUTICALS CORP. (US) | 2015-08-18 | — | — | US | disclosed |
| US-9101614-B2 | Method for treating non-Hodgkin's lymphoma | SYNTA PHARMACEUTICALS CORP. (US) | 2015-08-11 | — | — | US | disclosed |
| US-20100273846-A1 | METHOD FOR TREATING PROLIFERATIVE DISORDERS ASSOCIATED WITH MUTATIONS IN C-MET | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2010-10-28 | — | — | US | disclosed |
| US-20100249185-A1 | METHOD FOR INHIBITING TOPOISOMERASE II | SYNTA PHARMACEUTICALS CORP. | 2010-09-30 | — | — | US | disclosed |
| US-20080125587-A1 | Synthesis of triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. | 2008-05-29 | — | — | US | disclosed |
| US-20080004276-A1 | Method for treating non-hodgkin's lymphoma | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
| WO-2007139952-A2 | METHOD FOR THE PREPARATION OF TRIAZOLE COMPOUNDS WITH HSP90 MODULATING ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125587-A1 | Synthesis of triazole compounds that modulate HSP90 activity | HSP90AB1, HSP90AA1, HSP90AB2P | MAPT 63/4885TSHR 2300/4885RAB9A 3603/4885 |
| US-20100093717-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90AA1, HSP90AB2P | MAPT 1902/4885TSHR 3678/4885RAB9A 3621/4885 |
| US-20080004276-A1 | Method for treating non-hodgkin's lymphoma | HSP90AB1, HSP90AB2P, HSP90B1 | MAPT 3136/4885TSHR 4132/4885RAB9A 3565/4885 |
| US-20100249185-A1 | METHOD FOR INHIBITING TOPOISOMERASE II | TOP2A, TOP2B, TOP1 | MAPT 2928/4885TSHR 4054/4885RAB9A 4216/4885 |
| US-20190144398-A1 | METHOD FOR TREATING INFLAMMATORY DISORDERS | TNF, IL2, IL5 | MAPT 2687/4885TSHR 3754/4885RAB9A 4236/4885 |
| US-20170320837-A1 | METHOD FOR TREATING INFLAMMATORY DISORDERS | TNF, IL2, IL5 | MAPT 2687/4885TSHR 3754/4885RAB9A 4236/4885 |
| US-20100273846-A1 | METHOD FOR TREATING PROLIFERATIVE DISORDERS ASSOCIATED WITH MUTATIONS IN C-MET | HSP90AB1, HSP90B1, HSP90AA1 | MAPT 3028/4885TSHR 3413/4885RAB9A 2890/4885 |
| US-20060167070-A1 | heat shock protein 90 inhibitors such as 3-(2-Hydroxyphenyl)-4-(naphthalen-1-yl)-5-mercapto-triazole, used for for preventing or treating hyperproliferative disorders, such as cancer | HSP90AB1, HSP90AB2P, HSP90AA1 | MAPT 2876/4885TSHR 4401/4885RAB9A 3937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.